找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Ronald T. Borchardt,Edward H. Kerns,James L. Steve Book 2006 Springer-Ve

[復(fù)制鏈接]
查看: 46291|回復(fù): 56
樓主
發(fā)表于 2025-3-21 19:43:27 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
編輯Ronald T. Borchardt,Edward H. Kerns,James L. Steve
視頻videohttp://file.papertrans.cn/704/703359/703359.mp4
概述Outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process.Emphasis on advancing higher quality drug candidat
叢書(shū)名稱Biotechnology: Pharmaceutical Aspects
圖書(shū)封面Titlebook: Optimizing the
描述Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of thi
出版日期Book 2006
關(guān)鍵詞Borchardt; Discovery; Drug; Leads; Like; Optimizing; Properties; lead
版次1
doihttps://doi.org/10.1007/978-0-387-44961-6
isbn_softcover978-1-4939-5047-8
isbn_ebook978-0-387-44961-6
copyrightSpringer-Verlag New York 2006
The information of publication is updating

書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery影響因子(影響力)




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery影響因子(影響力)學(xué)科排名




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery被引頻次




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery被引頻次學(xué)科排名




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery年度引用




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery年度引用學(xué)科排名




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery讀者反饋




書(shū)目名稱Optimizing the "Drug-Like" Properties of Leads in Drug Discovery讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:32:50 | 只看該作者
Metabolic Activation-Role in Toxicity and Idiosyncratic Reactions,ole of chemically reactive metabolites has been well recognized (.). Type B reactions, also referred to as idiosyncratic or hypersensitivity reactions, have been the subject of extensive reviews in recent years (., .). These are generally believed to be immune mediated, and are not predictable from
板凳
發(fā)表于 2025-3-22 02:08:49 | 只看該作者
,Case History — Use of ADME Studies for Optimization of Drug Candidates, Vd) in the body, and cleared from the body through metabolism and excretion. The area under the drug plasma concentration versus time curve (AUC) provides an indirect assessment of the exposure level and duration of action of the therapeutic agent at the site of action (e.g. synovial fluid, tumor,
地板
發(fā)表于 2025-3-22 06:58:38 | 只看該作者
Computational Models Supporting Lead Optimization in Drug Discovery,, it can increase metabolic clearance, thus making difficult sustaining the pharmacologically relevant systemic exposure. In contrast, permeability, in many cases, increases with increasing lipophilicity, favoring absorption (.; .). The actual result will be determined by the relative contributions
5#
發(fā)表于 2025-3-22 11:21:45 | 只看該作者
6#
發(fā)表于 2025-3-22 14:33:55 | 只看該作者
7#
發(fā)表于 2025-3-22 19:24:35 | 只看該作者
8#
發(fā)表于 2025-3-22 21:13:29 | 只看該作者
9#
發(fā)表于 2025-3-23 02:02:19 | 只看該作者
10#
發(fā)表于 2025-3-23 06:06:22 | 只看該作者
Book 2006nd clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of thi
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 14:24
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
黄陵县| 乌拉特中旗| 武邑县| 噶尔县| 兰州市| 全南县| 湖州市| 应用必备| 红桥区| 武汉市| 望城县| 昔阳县| 波密县| 牙克石市| 武胜县| 西青区| 靖江市| 炉霍县| 苗栗县| 松溪县| 渝北区| 岫岩| 徐州市| 景泰县| 陈巴尔虎旗| 登封市| 万州区| 清远市| 德惠市| 阿鲁科尔沁旗| 专栏| 通道| 阳城县| 鸡东县| 盘锦市| 闵行区| 鄂伦春自治旗| 深圳市| 乌拉特前旗| 望奎县| 镇坪县|